Aceruloplasminemia

Neuropathology

Volumn 35, Issue 1, 2015, Pages 83-90

  Miyajima, Hiroaki ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Ceruloplasmin; Ferroportin; Ferroxidase; Hepcidin; Iron; Iron metabolic cycle; Neurodegeneration

Indexed keywords

CERULOPLASMIN; DEFEROXAMINE; FERROPORTIN; FERROUS ION; GLYCOSYLPHOSPHATIDYLINOSITOL; INSULIN; IRON; IRON CHELATING AGENT; TRANSFERRIN; ZINC SULFATE;

ACERULOPLASMINEMIA; ARTICLE; ASTROCYTE; BASAL GANGLION; BRAIN; CELL LOSS; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CEREBELLUM; CERULOPLASMIN BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CYTOSOL; DIABETES MELLITUS; EARLY DIAGNOSIS; HEMOCHROMATOSIS; HUMAN; INSULIN TREATMENT; IRON METABOLISM; IRON OVERLOAD; IRON TRANSPORT; LIPID PEROXIDATION; NERVE CELL; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROIMAGING; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; RETINA DEGENERATION; THALAMUS; DEFICIENCY; DEGENERATIVE DISEASE; ENZYMOLOGY; IRON METABOLISM DISORDER; METABOLIC ENCEPHALOPATHY; METABOLISM; PATHOLOGY;

ASTROCYTES; BRAIN DISEASES, METABOLIC, INBORN; CERULOPLASMIN; HUMANS; IRON; IRON METABOLISM DISORDERS; NEURODEGENERATIVE DISEASES; NEURONS;

EID: 84920948265     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/neup.12149     Document Type: Article

References (34)

1. Miyajima H, Nishimura Y, Mizoguchi K, Sakamoto M, Shimizu T, Honda N. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology 1987; 37: 761-767.
2. Harris ZL, Takahashi Y, Miyajima H, Serizawa M, MacGillivray RT, Gitlin JD. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci U S A 1995; 92: 2539-2543.
3. Miyajima H, Kono S, Takahashi Y, Sugimoto M. Increased lipid peroxidation and mitochondrial dysfunction in aceruloplasminemia brains. Blood Cells Mol Dis 2002; 29: 433-438.
4. Hellman NE, Gitlin JD. Ceruloplasmin metabolism and function. Annu Rev Nutr 2002; 22: 439-458.
5. Patel BN, Dunn RJ, David S. Alternative RNA splicing generates a glycosylphosphatidylinositol-anchored form of ceruloplasmin in mammalian brain. J Biol Chem 2000; 275: 4305-4310.
6. Kono S. Aceruloplasminemia. Curr Drug Target 2012; 13: 1190-1199.
7. Shiva S, Wang X, Ringwood LA etal. Ceruloplasmin is a NO oxidase and nitrite synthase that determines endocrine NO homeostasis. Nat Chem Biol 2006; 2: 486-493.
8. Samokyszyn VM, Miller DM, Reif DW, Aust SD. Inhibition of superoxide and ferritin-dependent lipid peroxidation by ceruloplasmin. J Biol Chem 1989; 264: 21-26.
9. Jeong SY, David S. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J Biol Chem 2003; 278: 27144-27148.
10. Nemeth E, Tuttle MS, Powelson J etal. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093.
11. De Domenico I, Ward DM, di Patti MC etal. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. EMBO J 2007; 26: 2823-2831.
12. Kono S, Yoshida K, Tomosugi N etal. Biological effects of mutant ceruloplasmin on hepcidin-mediated internalization of ferroportin. Biochim Biophys Acta 2010; 1802: 968-975.
13. Kaneko Y, Miyajima H, Piperno A etal. Measurement of serum hepcidin-25 levels as a potential test for diagnosing hemochromatosis and related disorders. J Gastroenterol 2010; 45: 1163-1171.
14. Guo P, Cui R, Chang YZ etal. Hepcidin, an antimicrobial peptide is downregulated in ceruloplasmin-deficient mice. Peptides 2009; 30: 262-266.
15. Miyajima H, Kohno S, Takahashi Y, Yonekawa O, Kanno T. Estimation of the gene frequency of aceruloplasminemia in Japan. Neurology 1999; 53: 617-619.
16. Daimon M, Yamatani K, Tominaga M, Manaka H, Kato T, Sasaki H. NIDDM with a ceruloplasmin gene mutation. Diabetes Care 1997; 20: 678.
17. Miyajima H. Aceruloplasminemia, an iron metabolic disorder. Neuropathology 2003; 23: 345-350.
18. McNeill A, Birchall D, Hayflick SJ etal. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 2008; 70: 1614-1619.
19. Mitsumori F, Watanabe H, Takaya N. Estimation of brain iron concentration in vivo using a linear relationship between regional iron and apparent transverse relaxation rate of the tissue water at 4.7T. Magn Reson Med 2009; 62: 1326-1330.
20. th Experiment Nuclear Magnetic Resonance Conference, April 2013.
21. Hellman NE, Schaefer M, Gehrke S etal. Hepatic iron overload in aceruloplasminaemia. Gut 2000; 47: 858-860.
22. McNeill A, Pandolfo M, Kuhn J, Shang H, Miyajima H. The neurological presentation of ceruloplasmin gene mutations. Eur Neurol 2008; 60: 200-205.
23. Morita H, Ikeda S, Yamamoto K etal. Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. Ann Neurol 1995; 37: 646-656.
24. Gonzalez-Cuyar LF, Perry G, Miyajima H etal. Redox active iron accumulation in aceruloplasminemia. Neuropathology 2008; 28: 466-471.
25. Oide T, Yoshida K, Kaneko K, Ohta M, Arima K. Iron overload and antioxidative role of perivascular astrocytes in aceruloplasminemia. Neuropathol Appl Neurobiol 2006; 32: 170-176.
26. Kaneko K, Yoshida K, Arima K etal. Astrocytic deformity and globular structures are characteristic of the brains of patients with aceruloplasminemia. J Neuropathol Exp Neurol 2002; 61: 1069-1077.
27. Kaneko K, Nakamura A, Yoshida K, Kametani F, Higuchi K, Ikeda S. Glial fibrillary acidic protein is greatly modified by oxidative stress in aceruloplasminemia brain. Free Radic Res 2002; 36: 303-306.
28. Patel BN, Dunn RJ, Jeong SY, Zhu Q, Julien JP, David S. Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. J Neurosci 2002; 22: 6578-6586.
29. Duce JA, Tsatsanis A, Cater MA etal. An iron-export ferroxidase activity of beta-amyloid protein precursor is inhibited by zinc in Alzheimer's Disease. Cell 2010; 142: 857-867.
30. Moos T, Rosengren Nielsen T, Skjørringe T, Morgan EH. Iron trafficking inside the brain. J Neurochem 2007; 103: 1730-1740.
31. Jeong SY, David S. Age-related changes in iron homeostasis and cell death in the cerebellum of ceruloplasmin-deficient mice. J Neurosci 2006; 26: 9810-9819.
32. Miyajima H, Takahashi Y, Kamata T, Shimizu H, Sakai N, Gitlin JD. Use of desferrioxamine in the treatment of aceruloplasminemia. Ann Neurol 1997; 41: 404-407.
33. Skidmore FM, Drago V, Foster P, Schmalfuss IM, Heilman KM, Streiff RR. Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation. J Neurol Neurosurg Psychiatry 2008; 79: 467-470.
34. Kuhn J, Bewermeyer H, Miyajima H, Takahashi Y, Kuhn KF, Hoogenraad TU. Treatment of symptomatic heterozygous aceruloplasminemia with oral zinc sulphate. Brain Dev 2007; 29: 450-453.